Those results indicated that a greater duration of response was achieved by nivolumab, relating to a long-term survival advantage. Nevertheless, in CheckMate 026 trial, among patients who had untreated NSCLC with PD-L1 expression ≥ 5%, the PFS of nivolumab group was shorter than that of ...
The involvement of cabozantinib in the development of fulminant type 1 diabetes with long-term nivolumab use, which has not been reported previously, is unknown, but caution may be necessary in terms of glycemic control in combination therapy with nivolumab and cabozantinib....
A term for diseases in which abnormal cells divide without control and can invade nearby tissues. Cancer cells can also spread to other parts of the body through the blood and lymph systems. Chemotherapy Treatment that uses drugs to stop the growth of cancer cells, either by killing the cells...
“These results suggest that the superior efficacy of nivolumab plus ipilimumab vs sunitinib with extended follow-up continues to come with the additional benefit of improved long-term HRQOL and reduced disease-related symptoms in patients with [advanced] RCC.”...
5,6 In CheckMate 040, nivolumab monotherapy demonstrated manageable safety, objective response rate (ORR) of 14%, duration of response of at least 12 months in 59% of patients, and promising long-term median survival of 15.1 months in patients with advanced HCC treated with sorafenib.5,7 ...
At the 2021 ESMO Congress, Janjigian presented the first results of the nivolumab/ipilimumab arm, as well as long-term follow-up from the nivolumab/chemotherapy arm of CheckMate-649. The coprimary end points were PFS and OS via blinded independent centr...
9016 Background: 1L NIVO + IPI was shown to provide durable long-term overall survival (OS) benefit vs chemo regardless of tumor programmed death ligand 1 (PD-L1) expression in patients (pts) with advanced NSCLC in CheckMate 227 Part 1 (NCT02477826); 3-year OS rates were 33% vs 22% ...
Here we report both long-term follow-up results comparing nivolumab plus chemotherapy versus chemotherapy alone and the first results comparing nivolumab plus ipilimumab versus chemotherapy alone from CheckMate 649. After the 24.0-month minimum follow-up, nivolumab plus chemotherapy continued to demonstrate...
et al. Long-term results of combined-modality therapy in resectable non-small-cell lung cancer. J. Clin. Oncol. 20, 1989–1995 (2002). Article PubMed Google Scholar Pignon, J. P. et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J. Clin. ...
as well as continue monitoring for any long-term toxicity. Planned exploratory analysis of longitudinal CSF samples collected in this study, including cytokine, cell-free DNA and single-cell RNA sequencing analysis, will also assess for dose-dependent effects of IT nivolumab, and/or factors that ...